Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04205552
Title Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)
Acronym NEOpredict
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Essen
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | DEU | BEL


No variant requirements are available.